Because the potential therapeutic effects of specific inhibitors of rRNA transcription without the effects of the health and body weights of mice were reported [40–43], our results suggest that the regulation of the KDM2A- and HP1γ-dependent mechanisms controlling rRNA transcription may be applicable to the treatment of breast cancer. This evidence concerns the gene KDM2A and breast carcinoma.